Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Reader Login
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 419  
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Citation statistics : Table of Contents
   2017| July-September  | Volume 16 | Issue 3  
    Online since May 30, 2017

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Cited Viewed PDF
ORIGINAL ARTICLES
A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: An initial experience
Manoj Gupta, Partha S Choudhury, Dibyamohan Hazarika, Sudhir Rawal
July-September 2017, 16(3):186-191
DOI:10.4103/1450-1147.207272  PMID:28670175
Lymph node staging plays an important role in planning initial management in nonmetastatic prostate cancer. This article compares the role of 68Gallium (68Ga)-prostate specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) with magnetic resonance imaging (MRI), which is considered the standard staging modality. Out of 39 high-risk prostate cancer patients who underwent 68Ga-PSMA PET-CT for staging (December 2014–December 2015), 12 patients underwent radical prostatectomy along with ePLND and were included in the analysis. Findings of the PSMA PET and MRI were compared with final histopathology. Sensitivity, specificity, positive predicative value (PPV), negative predicative value (NPV), and accuracy of 68Ga-PSMA PET-CT and MRI were calculated for numbers of patients and pelvic lymph node metastasis. Chi-square test, McNemar's test, and receiver operating characteristic (ROC) analysis were also done. 68Ga-PSMA PET-CT and MRI sensitivity, specificity, PPV, NPV, and accuracy for number of patients detection were 100%, 80%, 87.5%, 100%, 91.67%, and 57.14%, 80%, 80%, 57.4%, 66.67%, respectively. For detection of metastatic lymph node, it was 66.67%, 98.61%, 85.71%, 95.95%, 95.06% and 25.93%, 98.61%, 70%, 91.42%, 90.53%, respectively. Difference of lymph nodal detectability was statistically significant on Chi-square test. On McNemar's test,P value was statistically insignificant for number of patient detection (P = 0.250) but statistically significant for lymph nodal detection (P = 0.001) for 68Ga-PSMA PET-CT. In ROC analysis, area under the curve was also significantly high for lymph node detectability by 68Ga-PSMA PET-CT. Our initial experience shows that 68GaPSMA PET-CT is a very promising tracer for N staging in the initial workup of prostate cancer. It has the potential to impact patient's initial management and can up- and down-stage effectively.
  33 3,313 576
REVIEW ARTICLE
Systematic review on the accuracy of positron emission tomography/computed tomography and positron emission tomography/magnetic resonance imaging in the management of ovarian cancer: Is functional information really needed?
Subapriya Suppiah, Wing Liong Chang, Hasyma Abu Hassan, Chalermrat Kaewput, Andi Anggeriana Andi Asri, Fathinul Fikri Ahmad Saad, Abdul Jalil Nordin, Sobhan Vinjamuri
July-September 2017, 16(3):176-185
DOI:10.4103/wjnm.WJNM_31_17  PMID:28670174
Ovarian cancer (OC) often presents at an advanced stage with frequent relapses despite optimal treatment; thus, accurate staging and restaging are required for improving treatment outcomes and prognostication. Conventionally, staging of OC is performed using contrast-enhanced computed tomography (CT). Nevertheless, recent advances in the field of hybrid imaging have made positron emission tomography/CT (PET/CT) and PET/magnetic resonance imaging (PET/MRI) as emerging potential noninvasive imaging tools for improved management of OC. Several studies have championed the role of PET/CT for the detection of recurrence and prognostication of OC. We provide a systematic review and meta-analysis of the latest publications regarding the role of molecular imaging in the management of OC. We retrieved 57 original research articles with one article having overlap in both diagnosis and staging; 10 articles (734 patients) regarding the role of PET/CT in diagnosis of OC; 12 articles (604 patients) regarding staging of OC; 22 studies (1429 patients) for detection of recurrence; and 13 articles for prognostication and assessment of treatment response. We calculated pooled sensitivity and specificity of PET/CT performance in various aspects of imaging of OC. We also discussed the emerging role of PET/MRI in the management of OC. We aim to give the readers and objective overview on the role of molecular imaging in the management of OC.
  13 3,364 703
ORIGINAL ARTICLES
18F-fluorodeoxyglucose-positron emission tomography/computed tomography imaging of metastatic nasopharyngeal cancer with emphasis on the distribution of bone metastases
Ammad Shanoon Al Tamimi, Sumbul Zaheer, David Chee Ng, Saabry Osmany
July-September 2017, 16(3):192-196
DOI:10.4103/1450-1147.207273  PMID:28670176
Distant metastases change the prognosis of patients with nasopharyngeal carcinoma (NPC) which most commonly metastasizes to the bone. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) is reported as useful in imaging NPC metastases. Our study assesses the incidence and distribution of bone metastases detected by 18F-FDG PET/CT in NPC. 717 18F-FDG PET/CT scan reports of histologically proven NPC patients imaged in Singapore General Hospital, Singapore, between 2003 and 2009 were reviewed for the total number of metastases (scanned from vertex to mid-thigh) and analyzed for distribution. Of the 709 FDG avid metastases in these reports, 357/709 (50.35%) were locoregional nodal metastasis and 352/709 (49.65%) were distant metastases of which 192/709 (27.08%) of total metastases and 54.54% of distant metastases (192/352) were in the bones. The majority of the bone lesions 125/192 (65.1%) were in the axial skeleton with 109/192 (56.77%) in the lower skeleton (thoracolumbar spine, sacrum, and pelvis). The incidence of bone metastases in our study (27.08%) was higher than that reported in other studies, for example, 15% by Liu et al. and 11% (230 patients) by Caglar et al. Bone metastases have been reported in the femurs and the feet and as such some metastases may have been outside the field of view of the scans. In our study, 27% of FDG avid NPC metastases are in the bones.
  4 1,713 222
CASE REPORTS
An uncommon variant of an uncommon disease: A Caucasian adolescent with apical hypertrophic cardiomyopathy diagnosed with myocardial perfusion imaging
Rami Kassem Zein, Zaid Al-Faham, Jason A Mouabbi, Edouard R Daher
July-September 2017, 16(3):251-254
DOI:10.4103/1450-1147.207285  PMID:28670188
Apical hypertrophic cardiomyopathy (ApHCM) is a subtype of HCM. This variant is more common in the Asian population when compared to North American patients. Patients may present with arrhythmias, heart failure, myocardial infarction, chest discomfort, fatigue, and presyncope or syncope. Initial evaluation requires electrocardiogram and two-dimensional echocardiogram. T-wave inversion in the precordial leads as well as hypertrophy of the left ventricle is hallmarks of the disease. Cardiac magnetic resonance (CMR) imaging is the most specific and sensitive imaging modality. In patients with contraindications for CMR, myocardial perfusion imaging (MPI) has been described to have diagnostic characteristics for ApHCM. MPI images demonstrating a “solar polar” map pattern and increased apical tracer uptake in single-photon emission computed tomography horizontally and vertical long-axis slices are consistent with the diagnosis of ApHCM. Herein, we present a case of a Caucasian adolescent female who underwent a cardiac screening to rule out hypertrophic obstructive cardiomyopathy. Initially, the patient was unable to undergo CMR, and an MPI was utilized to assist with the diagnosis of ApHCM.
  3 1,782 194
ORIGINAL ARTICLES
Association of preoperative serum thyroid-stimulating hormone levels with thyroid cancer in patients with nodular thyroid disease
Muhammad Aleem Khan, Nadeem Malik, Kamran Hakeem Khan, Muhammad Faheem Shahzad
July-September 2017, 16(3):202-205
DOI:10.4103/1450-1147.207277  PMID:28670178
The aim of the current study was to determine the frequency of carcinoma thyroid among patients presenting with goiter and its association with preoperative serum thyroid-stimulating hormone (TSH) levels. A total of 73 (n = 73) adult patients of either gender with solitary solid cold nodule and multinodular goiter with predominant solid cold nodule were analyzed. All surgically resected samples were sent for histopathology. The frequency of thyroid cancer and its subtypes was noted and tested for association with preoperative serum TSH values. Thyroid cancer was diagnosed in 26% (n = 19) of the patients. In patients with thyroid cancer (n = 19), 73.7% (n = 14) were diagnosed with papillary thyroid cancer and 26.3% (n = 5) were diagnosed with follicular thyroid cancer. Presence of thyroid cancer was found to be significantly associated with preoperative higher mean TSH values (P < 0.05). Higher preoperative serum TSH levels may be useful in predicting thyroid cancer in nodular thyroid disease. Further studies are recommended with different cutoff values of serum TSH and its association with the development and progression of thyroid cancer.
  3 1,812 252
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
Pradeep Thapa, Rahul Parghane, Sandip Basu
July-September 2017, 16(3):223-228
DOI:10.4103/1450-1147.207283  PMID:28670182
The present study aimed at exploring the patient and imaging characteristics of primary neuroendocrine tumors (NETs) of rare sites who presented with metastatic and/or advanced inoperable stages and therefore was considered for peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE. A retrospective analysis was undertaken of these patients focusing on the aforementioned aspects. All patients underwent dual-tracer molecular functional imaging with somatostatin receptor (SSTR)-based imaging (with either 99mTc-HYNIC-TOC or 68Ga-DOTATATE) and 18fluorine fludeoxyglucose positron emission tomography-computed tomography as the pretherapy assessment. Based on the qualitative uptake of tracer in SSTR imaging, the lesions were divided into four categories Grade 0–III. The response was assessed post-PRRT by three parameters: (i) symptomatic response, (ii) biochemical response (serum tumor marker), and (iii) objective imaging response. The response profiles under each of these scales were assessed utilizing predefined criteria (detailed in methods). The overall response classification into partial response, stable disease, and progressive disease was done based on documentation of similar scale/category of at least two parameters among the triple parametric assessment. A total of nine patients (7 males, 2 females; age range: 33–59 years) with rare site primary NET were found: The primary sites included ureter (n = 1), sacrococcygeal (n = 1), esophagus (n = 1), thymus (n = 3), and mediastinum (n = 3). Treatment response assessment was undertaken in eight patients who received more than 2 cycles of PRRT with 177Lu-DOTATATE. In this response assessment group (n = 8), the patients received 2–5 cycles and follow-up duration ranged from 5 to 48 months. Symptomatic responses and better quality of life were observed in 4/8 (50%) patients, stable symptomatic disease in 3/8 (37.5%), and progression in 1/8 patients (12.5%). Biochemically, partial response was seen in 3/8 (37.5%), stable values was seen in 3/8 (37.5%), and progression of tumor marker was seen in 2/8 (25%) patients. Morphologically, partial response was seen in 2/8 (25%), stable disease in 5/8 (62.5%), and progressive disease in 1/8 (12.5%) patients. On overall assessment, 2/8 patients (25%) demonstrated partial response, 4/8 stable disease (50%), and 2/8 progressive disease (25%) at the time of assessment. As per the RECIST 1.1, seven patients had stable disease and one patient had progressive disease. No specific correlation could be obtained between dual-tracer molecular imaging features and the response likely due to small population of the study group. Overall, there was evidence of excellent disease stabilization, and symptom palliation with 177Lu-DOTATATE PRRT was documented in these advanced or metastatic NETs of various rare sites.
  2 1,858 293
Prostate-specific antigen and prostate-specific antigen kinetics in predicting 18F-sodium fluoride positron emission tomography-computed tomography positivity for first bone metastases in patients with biochemical recurrence after radical prostatectomy
James Yoon, Leslie Ballas, Bhushan Desai, Hossein Jadvar
July-September 2017, 16(3):229-236
DOI:10.4103/1450-1147.207286  PMID:28670183
We evaluated the association between serum prostate specific antigen (PSA) level and kinetics to predict 18F-sodium fluoride positron emission tomography-computed tomography (18F-NaF PET-CT) positivity for first bone metastases in men with biochemical recurrence after radical prostatectomy. All 18F-NaF PET-CT scans that were performed at our institution during 2010–2014 were queried to find patients who demonstrated biochemical recurrence after radical prostatectomy. Records were reviewed to obtain data on PSA levels and kinetics at the time of 18F-NaF PET-CT and pathologic features of the prostatectomy specimen, which were then used for receiver operating characteristic (ROC) analysis to determine predictability for 18F-NaF PET positivity. Thirty-six patients met our inclusion criteria. Of these, 8 (22.2%) had positive 18F-NaF PET-CT scans. Mean values for PSA, PSA doubling time (PSADT), and PSA velocity (PSAV) were 2.02 ng/ml (range: 0.06–11.7 ng/ml), 13.2 months (range: 1.11–60.84), and 1.28 ng/ml/year (range: 0.1–5.28) for 18F-NaF PET-CT negative scans, and 4.11 ng/ml (range: 0.04–14.38 ng/ml), 8.9 months (range; 0.7–27.8), and 9.06 ng/ml/year (range: 0.04–50.2) for 18F-NaF PET-CT positive scans, respectively (P = 0.07, 0.47, and 0.02, respectively, for PSA, PSADT, and PSAV). ROC analysis for 18F-NaF PET-CT positivity resulted in area under the curve (AUC) values of 0.634 for PSA, 0.598 for PSADT, and 0.688 for PSAV. ROC analysis with combined models gave AUC values of 0.723 for a combination of PSA and PSADT, 0.689 for a combination of PSA and PSAV, and 0.718 for grouping of PSA, PSADT, and PSAV. There was no significant association between 18F-NaF PET-CT positivity and primary tumor Gleason score, TN staging, and status of surgical margins. 18F-NaF PET-CT detected first-time osseous metastases in 22.2% of our patients with biochemical recurrence after prostatectomy with the PSA level range ≤11.7 ng/ml. PSAV was statistically significant in predicting 18F-NaF PET-CT positivity. ROC analysis demonstrated higher AUCs when PSA was combined with PSA kinetics parameters.
  2 1,670 193
CASE REPORTS
Unusual asymptomatic fluorodeoxyglucose avid pheochromocytoma in a case of myxoid liposarcoma of the extremity on 18-F fluorodeoxyglucose positron emission tomography-computed tomography
Divya Shivdasani, Natasha Singh, Melvika Pereira, Anand Zade
July-September 2017, 16(3):237-239
DOI:10.4103/1450-1147.207275  PMID:28670184
Sarcomas are a heterogeneous group of rare tumors and arise either from soft tissue or from bone. Soft-tissue sarcomas (STSs) initially metastasize to the lungs. Metastases to extrapulmonary sites such as liver, brain, and soft tissue distant from primary tumor usually develop later. However, cases with isolated adrenal metastasis without disseminated disease have been reported in literature. We present a case of primary myxoid liposarcoma of the lower limb, in which staging 18-F fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) scan detected a suspicious FDG avid adrenal lesion which eventually on resection was diagnosed as asymptomatic pheochromocytoma. Pheochromocytomas have been reported to demonstrate FDG uptake mimicking metastasis. Hence, while interpreting FDG PET-CT scans in the context of STSs, both the extrapulmonary metastatic potential of aggressive histological subtypes of sarcoma and rare possibility of FDG avid coexistent benign tumor should be taken into consideration.
  1 1,487 200
Presentation of unusual tracheal metastasis on Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography after 9 years in postnephrectomy patient of renal cell carcinoma: A case report and review of literature
Rahul Vithalrao Parghane, Ashwani Sood, Kim Vaiphei, Ashutosh Nath Aggarwal, Bhagwant Rai Mittal
July-September 2017, 16(3):240-242
DOI:10.4103/1450-1147.207280  PMID:28670185
Tracheal metastases from renal cell carcinoma (RCC) are extremely rare. Most common primary malignancy metastasizing to this unusual location usually comes from lung region while it is rare to have tracheal metastases from nonpulmonary malignancies such as breast, thyroid, colorectal carcinoma, and melanoma. The lesions detected on fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) scan, especially in the head and neck region, soft tissue, and muscular compartment during follow-up of RCC patients raise the possibility of metastatic lesions in these regions, though rarely encountered. F-18 FDG PET/CT proved to be a valuable noninvasive imaging tool in detecting the very unusual distant metastases and multisystem involvement many years after nephrectomy in RCC in a single session in the present case.
  1 1,458 169
Nuclear protein in testis midline carcinoma presenting in an infant as a pericardial mass with staging by 18F-fluorodeoxyglucose-positron emission tomography/computed tomography
Crystal Perkins, Darko Pucar, Colleen H McDonough, Hadyn T Williams
July-September 2017, 16(3):247-250
DOI:10.4103/1450-1147.207284  PMID:28670187
Nuclear protein in testis (NUT) midline carcinoma (NMC) is a rare, aggressive, lethal, epithelioid, poorly differentiated cancer first described in Japan in 1991, unique in that is defined genetically rather than by histological tissue of origin. It usually arises in the body midline and presents as a mass with metastasis. An infant presenting with pneumonia was found to have a pericardial mass, NMC resected, and subsequent staging positron emission tomography (PET) showing residual mediastinal tumor and midline abdominal metastases. Fewer than 100 cases of NMC have been reported in the literature, and PET appears to be the imaging modality of choice in complete staging and evaluation of treatment response.
  1 1,589 149
ORIGINAL ARTICLES
Transient ischemic dilation ratio in regadenoson, single isotope gated single-photon emission computed tomography myocardial perfusion imaging
Manolo Rubio, Andre Dias, Nikoloz Koshkelashvili, Jose N Codolosa, Mauricio Jalife-Bucay, Mary Rodriguez-Ziccardi, Aman M Amanullah
July-September 2017, 16(3):218-222
DOI:10.4103/1450-1147.207282  PMID:28670181
Single isotope 99mTc single-photon emission computed tomography-myocardial perfusion imaging (SPECT-MPI) is the most commonly used protocol for nuclear stress testing. Transient ischemic dilation of the left ventricle (TID) has been considered a specific marker of severe coronary artery disease (CAD). Recent publications have questioned the clinical utility of TID, specifically with regadenoson as a stressor and 4DM-SPECT software for TID analysis. These findings have not been demonstrated using other imaging packages. The goal of our study was to establish the TID threshold in the identification of Multi-vessel CAD using Quantitative Perfusion SPECT (QPS) software. Included in this study are 190 patients that had undergone regadenoson-stress, same day, single-isotope 99mTc MPI and had a coronary angiography within a designated 3-month period. QPS (Cedars-Sinai, LA, CA) automated image analysis software was used to calculate TID ratios which were compared across different CAD categories. Coronary angiograms were reviewed to identify both obstructive and nonobstructive CAD. The mean TID for patients with nonobstructive CAD (n = 91) was 1.02 ± 0.11, and the threshold for TID was 1.24. A receiver operating characteristic curve showed that TID had a poor discriminatory capacity to identify MVD (area under the curve 0.58) with a sensitivity of 3% and a specificity of 97%. In our study with regadenoson MPI in a predominantly African-American population, TID was found to be a poor predictor of MVD using QPS software. The reason is unclear but possibly related to the significant decline in the prevalence of severe CAD in the area where our study took place.
  1 2,117 230
CASE REPORTS
Unusual dipyridamole-induced aberrant conduction in the absence of myocardial ischemia
Roberto Ricca-Mallada, Federico Ferrando-Castagnetto, Rodolfo Ferrando, Fernando Mut
July-September 2017, 16(3):243-246
DOI:10.4103/1450-1147.207281  PMID:28670186
We report two patients referred to 2 day stress-rest single photon emission computed tomography for diagnosis of ischemia who elicited a transient left bundle branch block during dipyridamole intravenous infusion. The conduction disturbance disappeared after aminophyline infusion and became permanent during follow-up. Possible mechanisms underlying this unusual phenomenon in the absence of myocardial ischemia are discussed.
  - 2,462 135
EDITORIAL
Beware of editors bearing gifts
John R Buscombe
July-September 2017, 16(3):175-175
DOI:10.4103/wjnm.WJNM_37_17  PMID:28670173
  - 1,522 197
ORIGINAL ARTICLES
Positron emission tomography in mucosal melanomas of head and neck: Results from a South Asian tertiary cancer care center
Archi Agrawal, Gouri Pantvaidya, Vedang Murthy, Kumar Prabhash, Munita Bal, Nilendu Purandare, Sneha Shah, Venkatesh Rangarajan
July-September 2017, 16(3):197-201
DOI:10.4103/1450-1147.207274  PMID:28670177
To evaluate the accuracy of fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in staging and restaging of patients with mucosal melanomas (MM) of head and neck. Patients who underwent PET/CT at our institution, with a biopsy proven diagnosis of MM of the head and neck between March 2006 and December 2013 were included in the study. Nineteen patients with MM of the nasal cavity, paranasal sinuses, and oral cavity were included, of which 12 were for staging and seven for restaging. PET/CT had 100% sensitivity (SN), specificity (SP), positive predictive value (PPV), and negative predictive value (NPV) for detection of the primary. SN of 91.7%, SP of 100%, PPV of 100%, and NPV of 87.5% were seen for nodal metastases. For distant metastases, SN of 85.7%, SP of 100%, PPV of 100%, and NPV of 92.3% were noted. The disease was upstaged from loco-regional to metastatic in 32% leading to treatment change in 25% in the staging group and 43% in the restaging group. PET/CT demonstrates good overall accuracy in evaluation of patients with MM of the head and neck. The main strength of PET/CT lies in detection of distant metastatic disease due to extended whole-body field of view.
  - 1,662 199
Evaluation of diastolic function in patients with normal perfusion and type 2 diabetes mellitus with gated single-photon emission computed tomography
Ayse Nurdan Korkmaz, Billur Caliskan, Fatma Erdem
July-September 2017, 16(3):206-211
DOI:10.4103/1450-1147.207278  PMID:28670179
Early identification of diastolic dysfunction of patients with diabetes is important in preventing cardiac events. In this study, we aimed to show that both myocardial perfusion and diastolic function parameters can be evaluated in diabetic patients with possible silent cardiac symptoms using gated single-photon emission computed tomography (G-SPECT). We examined eighty patients: Forty with and forty without diabetes. The patients were compared in terms of systolic and diastolic parameters obtained using G-SPECT. 99mTc-sestamibi was used to obtain 8-frame images in each cardiac cycle, with calculation of the left ventricular ejection fraction (LVEF), peak filling rate (PFR), mean filling rate during the first third of diastolic time (MFR/3), and time to peak filling (TTPF) using the QGS software. G-SPECT results were compared in forty diabetic and forty nondiabetic patients of similar age and sex. Of the diastolic function parameters, PFR was found to be lower in patients with than without diabetes (2.31 ± 0.68 vs. 2.76 ± 0.68, respectively; P = 0.004). The TTPF and MFR/3 in both groups were similar. PFR was negatively correlated with end-diastolic volume and end-systolic volume (ESV) and positively correlated with LVEF. This correlation was stronger in patients with diabetes. The diastolic parameter PFR, obtained using G-SPECT, was significantly lower in patients with than without diabetes. We believe that these parameters should be noted for the early diagnosis or prevention of heart disease in patients with a risk of diastolic dysfunction.
  - 1,610 225
Demonstration of ischemia in myocardial perfusion scintigraphy before coronary revascularization decreases acute coronary syndrome-related hospitalizations
Hakki Kaya, Ozan Kandemir, Osman Beton, Tarik Kivrak, Recep Kurt, Mehmet Birhan Yilmaz
July-September 2017, 16(3):212-217
DOI:10.4103/1450-1147.207279  PMID:28670180
In this study, we compared the patients who underwent coronary angiography (CAG), followed by revascularization by coronary artery stent implantation according to the CAG results without any evidence of ischemia with myocardial perfusion scintigraphy (MPS), and the patients who underwent revascularization by coronary artery stent implantation following the detection of ischemia in MPS before CAG in terms of the mortality and hospitalization due to acute coronary syndrome (ACS). Between January 2009 and January 2016, a total of 407 patients (52% males, 48% females; mean age: 66 ± 9 years; range: 40–85 years) who underwent CAG following diagnosis of stable angina and underwent coronary artery stenting were retrospectively analyzed. The patients were divided into two groups: Group 1 (n = 200) included those who had MPS before CAG and in whom ischemia was detected and stent was implanted, and Group 2 (n = 207) included those who had stent implantation according to the CAG results without prior MPS. The mean follow-up was 40 ± 18 months. Although there was no significant difference in the mortality rates between the groups, the rate of hospitalization due to ACS was significantly lower in Group 1 (P = 0.112 vs.P = 0.022, respectively). According to the multivariate Cox-regression analysis, demonstration of ischemia in MPS before revascularization, statin use, clopidogrel use, and higher high-density lipoprotein cholesterol levels were found to be associated with a reduced risk of ACS-related hospitalization, whereas the presence of diabetes mellitus and smoking was found to be associated with an increased risk of ACS-related hospitalization.
  - 1,464 169
  Feedback 
  Subscribe